Table 2.

Current JAK inhibitors being investigated for atopic dermatitis.

Drug	Other names	Main target	Format
Abrocitinib	PF-04965842	JAK1	Oral
Upadacitinib	Rinvoqa	JAK1	Oral
Baricitinib	Olumiantb	JAK1, JAK2	Oral
Oclacitinib	Apoquelb	JAK1	Oral (veterinary)
Ruxolitinib	Jakafib and Jakavib	JAK1, JAK2	Topical
Delgocitinib	JTE-052	Pan-JAK	Topical

^aTrademark,

^bRegistered trademark.